npj Parkinson s DiseaseNeurosciencePeer-reviewed journal article
Interaction of G2019S LRRK2 and metabolic syndrome in a two-hit mouse model of Parkinson's disease: LRRK2-driven systemic depletion of pyrimidine nucleosides
Yue MaiD, Madalynn L. ErbiD, Kayla A. Sipple, Alina V. OffermaniD, Junwei Niu, Zachary MadajiD, Zhen FuiD, Kin H. LauiD, Darren J. MooreiD
Abstract
G2019S LRRK2 is the most common cause of familial Parkinsons disease (PD) and is associated with sporadic PD, arising from the interplay of genetic predisposition, environmental exposure and aging. Metabolic syndrome is implicated as a risk factor for PD, but the interaction between G2019S LRRK2 and metabolic stress in disease pathogenesis remains unclear. We employed high-fat diet (HFD) feeding to induce metabolic syndrome in aged mutant LRRK2 mice, followed by system-wide characterization, including metabolomic or proteomic profiling, and bulk or single-nucleus RNA sequencing. We find that thymidine and deoxyuridine levels are consistently reduced across tissues in G2019S LRRK2 knockin mice accompanied by increased hepatic expression of thymidine phosphorylase. HFD exposure further unmasks disruptions in purine and energy metabolism in brain and lung of G2019S LRRK2 knockin mice, with midbrain astrocytes and oligodendrocytes exhibiting the most pronounced impairment in oxidative phosphorylation transcriptional pathways. Our findings demonstrate that pre-existing metabolic syndrome unmasks widespread disruptions in systemic nucleotide and energy metabolism and exacerbates mitochondrial dysfunction in G2019S LRRK2 knockin mice. This conditional "two-hit" phenotype underscores the critical role of environmental factors, such as diet, in revealing metabolic vulnerabilities associated with PD-linked genetic backgrounds, and provides potential metabolic targets for therapeutic intervention in PD.
- organism: mouse
- assay: bulk RNA-seq
- assay: metabolomics
- research focus: differential expression
- approach: statistical model
- Citations
- 1
- FWCI
- 4.32
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dopaminergic Neurodegeneration Induced by Parkinson's Disease-Linked G2019S LRRK2 is Dependent on Kinase and GTPase Activity
An Phu Tran Nguyen, Elpida Tsika, … Darren J. Moore·Proceedings of the National Academy of SciencesPeer-reviewed·Jul 6, 2020
- Pharmacological rescue of impaired mitophagy in Parkinson's disease-related LRRK2 G2019S knock-in mice
F. Singh, A. R. Prescott, … I. Ganley·bioRxiv·Dec 7, 2020
- Parkinson's disease linked LRRK2 G2019S drives oxidative nuclear DNA damage and PARP1 hyperactive signaling
Jennifer Liu, Claudia P. González-Hunt, … Laurie H. Sanders·bioRxiv·Mar 1, 2026
- LRRK2 I1371V Impairs Astrocytic Glucose Metabolism and Triggers Multi-Organellar Dysfunction in PD
Roon Banerjee, Rashmi Santhoshkumar, … Indrani Datta·bioRxiv·Jan 21, 2026
- G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
Nicholas Pena, Tara Richbourg, … Laurie H. Sanders·npj Parkinson s DiseasePeer-reviewed·Mar 1, 2024
- LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread
Noah Lubben, Julia K. Brynildsen, … Michael X. Henderson·Translational NeurodegenerationPeer-reviewed·Mar 4, 2024